Michael Salgado's Archive

Michael is currently a junior at Moravian College working towards his BS in Biology. His main focus and interest is in Micro and Molecular Biology. Michael also holds a part time job at a hardware warehouse in Allentown, PA. As a writer for Light Knowledge Resources, Michael works to create helpful, meaningful content for The Myeloma Beacon. His interests include running, camping, hunting, fishing, and movies.

Michael Salgado has written 49 article(s) .

[ by | Dec 5, 2008 9:46 pm | Comments Off ]

Honolulu Marathon – The Team in Training, which is part of the Leukemia & Lymphoma Society (LLS), is raising money and competing on behalf of the LLS in the Honolulu Marathon on December 14. Events include a pleasant nine hour course and a 10K race. The Honolulu Marathon is considered one of the largest and most scenic marathons in the world.  Its course includes locations such as Waikiki Beach, Diamond Head, and Koko Head Craters.

Tags: , , ,
Read the full story »
[ by | Nov 20, 2008 10:49 pm | Comments Off ]

The International Myeloma Foundation (IMF) held its second annual Comedy Celebration benefiting The Peter Boyle Memorial Fund on Saturday in Los Angeles, California.

Peter Boyle was an Emmy Award-winning actor and was most recently well-known as the father, Frank Barone, on the CBS show Everybody Loves Raymond. Fellow cast members Ray Romano, Doris Roberts, and Patricia Heaton were among the guests at this year’s benefit.

The Peter Boyle Memorial Fund was started by his family in 2006 after his…

Tags: , ,
Read the full story »
[ by | Nov 16, 2008 2:01 am | Comments Off ]

Folic acid (vitamin B9), vitamin B6, and vitamin B12 are thought to play a role in preventing cancer and heart disease.

However, researchers at Harvard Medical School recently showed women who have a high risk of heart disease did not improve their risk of developing cancers, such as multiple myeloma, after taking the vitamins.

The study participants received a daily combination of folic acid, vitamin B6, and vitamin B12 or placebo for more than 7 years between…

Tags: , , , ,
Read the full story »
[ by | Nov 6, 2008 10:11 am | Comments Off ]

Prolexys Pharmaceuticals, Inc. raised $20 million from an investment by Friedli Corporate Finance. The investment will allow for Prolexys Pharmaceuticals to continue research on a unique molecule called PRLX 93936.

PRLX 93936 is significant to multiple myeloma patients because of its vigorous and selective anti-tumor activity. The drug shows promising action in disease models such as those of multiple myeloma and other cancers with less medical treatments and options.

Currently, PRLX 93936 is in Phase 1 study,…

Tags: ,
Read the full story »